Phenotype and genotype expression in pseudohomozygous factor V(LEIDEN): The need for phenotype analysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 2, 1999, Pages 336-342

  Kalafatis, Michael ^a,d   Bernardi, Francesco ^c   Simioni, Paolo ^b   Lunghi, Barbara ^c   Girolami, Antonio ^b   Mann, Kenneth G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Factor V(LEIDEN); Genotype; Phenotype; Pseudohomozygous; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; MESSENGER RNA;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; FEMALE; GENE EXPRESSION; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MALE; PATHOPHYSIOLOGY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN STABILITY; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0033043712     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.2.336     Document Type: Article

References (31)

1. Mann K, Nesheim M, Church W, Haley P, Krishnaswamy S. Surface dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990;76:1-16.
2. Jenny RJ, Pittman DD, Toole JJ, Kriz RW, Aldape RA, Hewick RM, Kaufman RJ, Mann KG. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A. 1987;84: 4846-4850.
3. Kalafatis M, Rand MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994;269:31869-31880.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369:64-67.
6. Koster T, Rosendaal FR, de Ronde H, Brie TE, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: the Leiden thrombophilia study. Lancet. 1994;342: 1503-1506.
7. Leiden and thrombophilia. Arterioscler Thromb Vasc Biol. 1997;17:620-627.
8. Zöller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1997;343:1536-1538.
9. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
10. R506Q. J Biol Chem. 1995;270:4053-4057.
11. van't Veer C, Kalafatis M, Bertina RM, Simioni P, Mann KG. Increased tissue factor initiated prothrombin activation as a result of the Arg506Gln mutation in factor VLeiden. J Biol Chem. 1997;272:20721-20729.
12. Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A. 'Pseudo homozygous' activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb Haemost. 1996;75: 422-426.
13. Zehnder JL, Jain M. Recurrent thrombosis due to compound heterozygosity for factor V Leiden and factor V deficiency. Blood Coagul Fibrinolysis. 1996;7:361-362.
14. Guasch JF, Lensen RPM, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is pseudo homozygous for activated protein C resistance. Thromb Haemost. 1997;77:252-257.
15. Greengard JS, Alhenc-Gelas M, Gandrille S, Emmerich J, Aiach M, Griffin JH. Pseudo homozygous protein C resistance due to coinheritance of heterozygous factor VR506Q and type I factor V deficiency associated with thrombosis. Thromb Haemost. 1995;73:1361a. Abstract.
16. Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood. 1982;60:59-63.
17. Castoldi E, Lunghi B, Mingozzi F, Ioannou P, Marchetti G, Bernardi F. New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V Leiden mutation in Mediterranean populations and Indians. Thromb Haemost. 1997;78: 1037-1041.
18. Sacchi E, Pinotti M, Marchetti G, Merati G, Tagliabue L, Mannucci PM, Bernardi F. Protein S mRNA in patients with protein S deficiency. Thromb Haemost. 1995;73:746-749.
19. Kalafatis M, Haley PE, Lu D, Bertina RM, Long GL, Mann KG. Proteolytic events that regulate factor V activity in whole plasma from normal and activated protein C (APC)-resistant individuals during clotting: an insight into the APC resistance assay. Blood. 1996;87: 4695-4707.
20. Trossaert M, Conard J, Horello MH, Samama MM. Influence of storage conditions on activated protein C resistance assay. Thromb Haemost. 1997;73:163-164.
21. Sidelmann J, Gram J, Pedersen OD, Jespersen J. Influence of plasma platelets on activated protein C assay. Thromb Haemost. 1995;74:993-994.
22. Engel H, Zwang L, Van Vliet HHDM, Michiels JJ, Stibbe J, Lindmans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost. 1996;76:267-269.
23. Cumming AM, Keeney S, Salden A, Shanks D, Hay CRM. Potential misdiagnosis of factor V Leiden: a comparison of two genotyping techniques. Thromb Haemost. 1997;77:1217.
24. Tosetto A, Missiaglia E, Gatto E, Rodeghiero F. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Thromb Haemost. 1997;78:859-863.
25. Tracy RP, Psaty BM, Tang Z, et al. Coagulation factor V genetic polymorphisms associated with cardiovascular disease in the elderly. Circulation. 1997;96(suppl I):I-100. Abstract.
26. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997;90:1552-1557.
27. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci U S A. 1994;91:1396-1400.
28. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in the degradation of factor VIIIa. J Biol Chem. 1994;269:18735-18738.
29. Lu D, Kalafatis M, Mann KG, Long GL. Comparison of activated protein C/protein S-mediated activation of human factor VIII and factor V. Blood. 1996;87:4708-4717.
30. Varadi K, Rosing J, Tans G, Pabinger I, Keil B, Schwartz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V R506Q mutation. Thromb Haemost. 1996;76:208-214.
31. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood. 1996;88:3432-3445.